Lexent Bio

Novel liquid biopsy technology to change the way we manage cancer

[Lexent Bio @lexentbio]

Today, we are proud to join @FoundationATCG, and to work together to change the way we understand and treat cancer https://t.co/KP1GvgG4vI

[New England Biolabs @NEBiolabs]

Don’t miss Nicole Lambert from @lexentbio in the Bronze sponsor workshop: "Monitoring cell-free methylation changes with enzymatic conversion to assess response to cancer treatments." Tuesday, Feb 25th, 3:15-3:30 PM. https://t.co/Lpz9vomJhI
#RNAseq #AGBT20

[Precision Medicine World Conference @PMWCintl]

How will genome profiling change the standard-of-care in the near and/or far future? Ted Snelgrove, @lexentbio, answered. Check it out.

Plus, only 10 days till #PMWC20! Tickets: https://t.co/0iD3DRCQpa

https://t.co/vQTK5T44FA

#genome #healthcare

[Lexent Bio @lexentbio]

Proud to be part of this great initiative https://t.co/RzlczBoAzn

[Friends of Cancer Research @CancerResrch]

Allen on ctMoniTR: “Working with multiple partners will develop the necessary evidence about the use of ctDNA in a way that is faster and more robust than if everyone continues to investigate it independently."

To learn more about our new project, visit: https://t.co/UD7uuXUmhk

[Lexent Bio @lexentbio]

Proud to be partnering with @illumina towards making Lexent response monitoring technology available as an IVD kit

[Illumina @illumina]

We are excited to partner with @lexentbio to develop an in vitro next-generation sequencing-based cancer diagnostic kit: https://t.co/aX5A6w8dix

[Lexent Bio @lexentbio]

Thanks for hosting this great workshop at #ASHG2019 - glad we could play a part!

[New England Biolabs @NEBiolabs]

Headed to #ASHG2019? Join us Thursday from 12:45-2pm for lunch and a workshop on "Advancing DNA Methylome Analysis" with presentations by Frank Wos of @nygenome and Nicole Lambert of @lexentbio. Plus be entered to win an Apple Watch®! Register at https://t.co/NhbfDABOMq
#NEBNext

[Haluk Tezcan @HTezcanMD]

It was an honor to be selected by @rdienstmann, a pioneer and thought leader in this field. #ESMO2019 #ESMO19 #cfDNA. Great collaboration with @NUFeinbergMed @lexentbio

[Lexent Bio @lexentbio]

Lexent Bio technology provides molecular response early in the course of cancer treatment. Liquid Biopsies Intensify Surveillance of ctDNA https://t.co/iM5pglAEcW via @GENbio

[DeciBio @DeciBio]

Liquid Biopsy Weekly: Spotlight on @lexentbio - study of 97 patients detects disease progression ~6 weeks before imaging, with Sn 54% and Sp 100%

Read more about this week's exciting activities in the #liquidbiopsy space here: https://t.co/VVlVkUJDwM

#ctDNA #decibio #weeklynews

[Lexent Bio @lexentbio]

Excellent reporting on our preprint manuscript @GenomeWeb https://t.co/kXfSsnP3q5

[Lexent Bio @lexentbio]

Our preprint is now available on @medrxivpreprint: Early detection of molecular disease progression by whole-genome circulating tumor DNA in advanced solid tumors https://t.co/ocK8WKRtRh

[Lexent Bio @lexentbio]

Thanks for the shout-out @vintweeta, and for your contributions to this space

[Vineeta Agarwala @vintweeta]

Optimistic about the work that @GrailBio @freenome @GuardantHealth @FoundationATCG @lexentbio and so many others are doing to systematically change the timepoints at which we acquire information about new cancer diagnoses as well as progression/resistance to therapy.

[Lexent Bio @lexentbio]

It's a beautiful day in SF for the #liquidbiopsysummit today! Looking forward to CMO @htezcan’s talk, "Towards Marker-Driven Treatment Management in Patients with Advanced Cancer"

[Lexent Bio @lexentbio]

The lines to see our posters are long but the wait is worth it. Come see our remarkable response monitoring clinical data this morning at #ASCO2019

[Lexent Bio @lexentbio]

Come visit us at #ASCO19 poster session June 1, 8-11 an Hall A Board #33 (Abst #3041 https://t.co/Zx9D0vQGMZ) & Board #34 (Abst #3042 https://t.co/Try31J8Bkq)

[Lexent Bio @lexentbio]

Our work "Serial changes in tumor-derived whole-genome cell-free DNA (cfDNA) fraction to identify early disease progression prior to imaging" that was presented at #AACR2019 #cfDNA #cancerresearch #WGS https://t.co/pkIeQcNz9u

[Lexent Bio @lexentbio]

Great turnout & fun to discuss so many good questions about our work on response monitoring at #AACR2019

[Lexent Bio @lexentbio]

Welcome Ted! https://t.co/FyZZo5ovab

[James Hadfield @coregenomics]

HT: @lexentbio use whole genome signals including methylation, Sequence Variants, local read counts and fragment characteristics to determine if patient in remission or is progressing.
#PMWC19

[Lexent Bio @lexentbio]

We’re looking forward to #PMWC19 next week! Join our CMO Dr Haluk Tezcan @HTezcanMD in the liquid biopsy showcase, Jan 21st at 145pm, for "Avoiding Ineffective Treatment Cycles With Liquid Biopsy". Bio and more on the topic: https://t.co/Ueh2T72Ltp #genomics #cancer